JEFFREY E GERSHENWALD to Antineoplastic Agents
This is a "connection" page, showing publications JEFFREY E GERSHENWALD has written about Antineoplastic Agents.
Connection Strength
0.182
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.028
-
Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. J Clin Oncol. 2016 Apr 01; 34(10):1079-86.
Score: 0.028
-
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015 Mar; 28(2):135-47.
Score: 0.025
-
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
Score: 0.017
-
Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 02; 99(5):734-40.
Score: 0.017
-
Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer. 2008 May 01; 112(9):2030-7.
Score: 0.016
-
Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia. 2006 Sep; 8(9):747-57.
Score: 0.014
-
Surgical clinical trials in melanoma. Surg Clin North Am. 2003 Apr; 83(2):385-403.
Score: 0.011
-
Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. J Natl Cancer Inst. 2016 09; 108(9).
Score: 0.007
-
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
Score: 0.005
-
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91.
Score: 0.005
-
Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res. 2008 Jun 01; 68(11):4392-7.
Score: 0.004
-
Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004 Jul 01; 86(4):212-23.
Score: 0.003